Enzyme selective inhibitors represent the most valuable experimental tool for reaction phenotyping. However, only a limited number of UDP-glucuronosyltransferase (UGT) enzyme selective inhibitors have been identified to date. This study characterized the UGT enzyme selectivity of niflumic acid (NFA). It was demonstrated that NFA, 2.5 µM, is a highly selective inhibitor of recombinant and human liver microsomal (HLM) UGT1A9 activity. Higher NFA concentrations (50 -100 µM) inhibited UGT1A1 and UGT2B15, but had little effect on the activities of UGT1A3, UGT1A4, UGT1A6, UGT2B4, UGT2B7 and UGT2B17. NFA inhibited 4-methylumbelliferone and propofol (PRO) glucuronidation by recombinant UGT1A9
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5 Given these features of human UGT enzymes, attention has focussed on the identification of enzyme-selective substrate and inhibitor probes for the reaction phenotyping of drug glucuronidation reactions. UGT enzyme selective substrates have been identified for the main human hepatic drug metabolizing UGTs and these may be employed in activity correlation studies in a panel of human liver microsomes (HLM) or hepatocytes (Court, 2005; Miners et al., 2006 and 2010a) . However, enzyme selective inhibitors represent a more valuable experimental tool for reaction phenotyping since the extent of inhibition of the glucuronidation of a test compound by HLM or hepatocytes reflects the contribution of the individual UGT enzymes to metabolic clearance. In contrast to the ready availability of substrate probes, only two UGT enzyme selective inhibitors have been identified to date. Hecogenin (10 µM) is a highly selective inhibitor of UGT1A4 (Uchaipichat et al., 2006a) and fluconazole (2500 µM) is a moderately selective inhibitor of UGT2B7 (Uchaipichat et al., 2006b) , although more recent studies suggest similar inhibition of UGT2B4 (Raungrut et al., 2010) . (Isolongifolol and a phenyl substituted secondary alcohol derived from this compound have been reported to be potent, selective inhibitors of recombinant UGT2B7 (Bichlmaier et al., 2007) , although experimental conditions for selective inhibition of human liver microsomal UGT2B7 appear not to have been characterized.)
While UGT1A1 appears to be the principal enzyme involved in the glucuronidation of the non-steroidal anti-inflammatory drug niflumic acid (NFA; Mano et al., 2006a) , it has been demonstrated that this compound potently inhibits 4-methylumbelliferone (4MU) glucuronidation by recombinant UGT1A9 (Gaganis et al., 2007; Mano et al., DMD #37036 6 2006b). In addition, it has been reported that NFA inhibits the glucuronidation of the predominantly UGT1A9 substrate mycophenolic acid with HLM as the enzyme source (Vietri et al., 2002) . However, high concentrations of NFA may also inhibit other UGT enzymes (Gaganis et al., 2007) . To investigate the potential utility of NFA as an inhibitor probe for the reaction phenotyping of drug glucuronidation reactions, this study characterized the concentration dependence of UGT enzyme inhibition by NFA and the mechanism of inhibition. The results demonstrated that, under appropriate experimental conditions, NFA selectively inhibits UGT1A9 and, to a lesser extent, UGT1A1 and UGT2B15.
Following demonstration of UGT enzyme selectivity, NFA inhibition was applied to the reaction phenotyping of acetaminophen (APAP; paracetamol) glucuronidation by HLM. Glucuronidation accounts for approximately 65% of the metabolic clearance of a therapeutic dose of APAP in humans (Miners et al., 1984) . Although APAP is one of the most widely used drugs worldwide, the relative contribution of individual UGT enzymes to APAP glucuronidation is yet to be completely resolved. While APAP glucuronidation is generally attributed to UGT 1A1, 1A6 and 1A9 (Bock et al., 1993; Court et al., 2001 ), more recently Mutlib et al. (2006) proposed a significant role for UGT2B15. Thus, NFA inhibition was used here to further explore the relative contribution each of these enzymes to APAP glucuronidation by HLM.
8 Ethics Committee. HLM were activated by pre-incubation with the pore-forming agent alamethicin (50 µg/mg microsomal protein) prior to use in incubations, as described by Boase and Miners (2002) .
Human UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, and 2B17 cDNAs were stably expressed in a human embryonic kidney cell line (HEK293T) (Uchaipichat et al., 2004) . After growth to at least 80% confluence, cells were harvested and washed in phosphate-buffered saline. Cells were subsequently lysed by sonication using a Vibra Cell VCX 130 Ultrasonics Processor (Sonics and Materials, Newtown, CT, USA). Lysates were centrifuged at 12,000 g for 1 min at 4°C, and the supernatant fraction was separated and stored in phosphate buffer (0.1 M, pH 7.4) at -80°C until use. Given the relatively higher expression of UGT 2B4, 2B7 and 2B15 in Sf cells, Supersomes expressing these proteins were used for activity and inhibition studies.
Expression of all UGT proteins was demonstrated by immunoblotting with a commercial UGT1A antibody (BD Gentest, Woburn, MA, USA) or a non-selective UGT antibody (raised against purified mouse Ugt) (Uchaipichat et al., 2004) , and by activity measurement (see below).
NFA inhibition of recombinant UGT enzyme activities
NFA was screened for inhibition of UGT 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, 2B15 and 2B17 activities using the non-selective UGT substrate 4MU as the probe. Incubations were performed at a 4MU concentration corresponding to the apparent K m or S 50 of each enzyme (Uchaipichat et al., 2004) , in the absence and presence of NFA (1, 10 and 100 μM). NFA stock solutions were prepared in DMSO such that the final concentration of solvent in incubations was 1% (v/v), which has a This article has not been copyedited and formatted. The final version may differ from this version. negligible or minor effect on most UGT activities (Uchaipichat et al., 2004 ). An equivalent volume of DMSO was included in control incubations. Protein concentrations and incubation time varied for each enzyme, and were as described by Uchaipichat et al. (2004) . Incubations, in a total volume of 200 μ l, contained, MgCl 2 (4 mM), UDPGA (5 mM), HEK293T cell lysate or Supersomes, and 4MU in phosphate buffer (0.1 M, pH 7.4). Reaction mixtures were pre-incubated at 37°C for 5 min prior to initiation of the reaction by addition of cofactor (UDPGA). Incubations were performed in air at 37°C (shaking water bath) for the specified time for each enzyme (Uchaipichat et al., 2004) , and then terminated by the addition of 70% of perchloric acid (2 µl). Mixtures were vortex mixed and centrifuged at 4000 x g for 10 min. Formation of 4MUG was quantified by HPLC following the procedure described by Lewis et al. (2007) .
Inhibition of UGT1A4 by NFA was assessed with LTG as the probe substrate according to Rowland et al. (2006) . Incubations, in a total volume of 200 μ l, contained, MgCl 2 (4 mM), UDPGA (5 mM), HEK293 cell lysate expressing UGT1A4
(1 mg/ml), LTG (1500 µM) and NFA (0, 10 and 100 uM). LTG 2-glucuronide was measured by HPLC (Rowland et al., 2006) . Effects of NFA on UGT2B4 activity were determined with COD as the substrate (Raungrut et al., 2010) . In brief, incubations in a total volume of 100 μ l, contained, MgCl 2 (4 mM), UDPGA (5 mM), Supersomes expressing UGT2B4 (1 mg/ml), COD (2000 µM), and NFA (0, 1, 10 and 100 μM).
Incubations were performed at 37˚C for 120 min. C6G formation was quantified by HPLC (Raungrut et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. Incubations characterizing human liver microsomal DEF 3-glucuronidation activity contained DEF (4,000 µM), HLM protein (0.5 mg/ml), MgCl 2 (4 mM) and UDPGA (5 mM) in phosphate buffer (200 µl; 0.1 M, pH 7.4). Reactions were performed for 60 min and 37ºC, after which time samples were treated with 70% HClO 4 (2 µl).
Following centrifugation (4,000 x g for 10 min), a 15 µl aliquot of the supernatant fraction was injected on to the HPLC column. HPLC was performed using 1100 series instrument (Agilent Technologies, Sydney, Australia) fitted with a Waters Novapak C18 analytical column (3.9 x 150 mm, 5 μm particle size; Waters, Milford, MA).
Analytes were detected by UV absorbtion at 280 nm. The mobile phase comprised of 5mM heptanesulfonic acid in water (pH 2.2) (A) and acetonitrile (B), delivered at a flow rate of 1 ml/min. Initial conditions were 98% A -2% B increasing linearly to 83% A -17% B over 10 min, which was held constant for 1.5 min before returning to the initial conditions. DEFG and DEF eluted at 4.9 and 8.8 min, respectively. DEFG was quantified by reference to a standard curve constructed using the authentic compound. Overall within-day assay reproducibility was assessed by measuring DEFG formation at low (0.5 mM) and high (10 mM) substrate concentrations on nine occasions with pooled HLM as the enzyme source. Within-day coefficients of variation were 3.5% and 1.6% at 0.5 and 10 mM, respectively.
Kinetic characterization of NFA inhibition of UGT1A1, UGT1A9, and UGT2B15
Mechanisms of inhibition and inhibitor constants for NFA inhibition of UGT1A1 and UGT1A9 were determined with the individual recombinant enzymes and with pooled HLM, while inhibition of UGT2B15 was characterized only with the recombinant enzyme (due to the lack of convenient selective probes suitable for measurement of microsomal enzyme activity). Incubation conditions were as described in previous 
UGT2B15. NFA inhibition of UGT2B15 glucuronidation was investigated using
Supersomes expressing UGT2B15 as the enzyme source and 4MU as the substrate.
Incubation and assay conditions were as described under UGT1A1. The Supersome protein concentration and incubation time were 0.25 mg/ml and 90 min, respectively.
Experiments to determine inhibitor constants included four NFA concentrations (20, 40, 60 and 80 µM) at each of three 4MU concentrations; 50, 150 and 300µM.
This article has not been copyedited and formatted. The final version may differ from this version. terminated by the addition of 70% HClO 4 (2µl) and then vortex mixed and centrifuged (4000 x g for 10 min). An identical procedure was employed for kinetic studies with recombinant UGTs, except the incubation time was increased to 120 min.
A 100 μl aliquot of the supernatant fraction was mixed with 15 μl of 1M sodium acetate to increase the pH of samples prior to analysis by HPLC. HPLC was performed using 1100 series instrument (Agilent Technologies) fitted with a Synergie
Hydro reverse-phase C18 analytical column (3 x 150 mm, 4 μm particle size ) (Phenomenex, Sydney, Australia). The mobile phase comprised glacial acetic acidacetonitrile -water (1:5:94). Analytes were eluted at a flow rate of 1 ml/min and detected by UV absorption at 243 nm. Under these conditions, retention times for APAPG and APAP were 1.7 and 3.5 min, respectively. APAPG concentrations in incubation mixtures were quantified by comparison of peak areas to those of an APAPG standard curve. Within-day overall assay reproducibility for the APAP glucuronidation assay was assessed by measuring the rate of APAPG formation in 
Data Analysis
All kinetic and inhibition experiments were performed in duplicate and data points represent the mean of duplicate estimates (<10% variance). APAP glucuronidation kinetic data were modeled using the Michaelis Menten equations for single and twoenzyme reactions, the Hill equation and the substrate inhibition equation (see Uchaipichat et al., 2004 for expressions) using EnzFitter version 2.0 (Biosoft, Cambridge, UK). Similarly, the mechanism of inhibition and K i values for NFA inhibition of UGT activities were determined by fitting the expressions for competitive, noncompetitive, uncompetitive and mixed inhibition to experimental data using Enzfitter. (Given the importance of mechanism of inhibition to the Results and their interpretation, equations corresponding to each mechanism are given below.)
Goodness of fit of all expressions was assessed from comparison of the parameter SE of fit, coefficient of determination (r 2 ), 95% confidence intervals, and F-statistic.
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where K i is the inhibitor constant for the EI and ESI complexes.
Mixed (competitive -non-competitive) inhibition:
where K i and K i ' are the inhibitor constants for the EI and ESI complexes, respectively. K i ' is related to K i by a factor, α (> 1), that is EI has a lower affinity for the substrate than does E (Segel 1993).
RESULTS
NFA inhibition of recombinant and human liver microsomal UGT enzyme activities
The selectivity of NFA as an inhibitor of human UGTs was characterized initially with recombinant proteins. 4MU was used as the probe substrate for the inhibition studies with UGT 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, 2B15 and 2B17. Since UGT1A4 and UGT2B4 exhibit low or negligible activity towards 4MU (Uchaipichat et al., 2004; Kubota et al., 2007) , LTG and COD were used as the respective substrates (Raungrut et al., 2010; Rowland et al., 2006) . NFA was a potent inhibitor of UGT1A7 and UGT1A9. The activity of both enzymes was abolished by 10µM NFA (Figure 1 ). UGT1A1, UGT1A6, UGT1A8, UGT1A10, UGT2B15 and UGT2B17 activities were inhibited by approximately 30% -90% at an added NFA concentration of 100µM, whereas UGT1A3, UGT1A4, UGT2B4 and UGT2B7 were inhibited by ≤ 25%. While inhibition of UGT1A7, UGT1A8 and UGT1A10 is notable, especially the potent effect of NFA on UGT1A7, inhibition of these enzymes was not studied further since expression in liver and kidney is minor or negligible (Ohno and Nakajin, 2009).
The results of inhibition screening studies of human liver microsomal UGT activities were broadly consistent with the recombinant enzyme data. PRO glucuronidation, a selective marker of hepatic UGT1A9 activity, was inhibited by 72% and 95% at NFA for NFA inhibition of UGT1A1 catalyzed 4MU and β -E2 glucuronidation (viz. 14 to 18 µM) were approximately 2-orders of magnitude higher than those observed for UGT1A9 (Table 1) . Given the lack of a convenient selective substrate probe for UGT2B15 suitable for studies with HLM, NFA inhibition of this enzyme was assessed with the recombinant protein and 4MU as substrate. Interestingly, NFA inhibition of UGT2B15 was competitive ( Figure 5 and Table 1 inhibition of UGT1A9 were close in value with both 4MU and PRO as the substrates.
As noted previously, the higher K i observed for human liver microsomal UGT1A9
probably reflects the greater inhibitory effect of long-chain unsaturated fatty acids with this enzyme source (Rowland et al., 2007 and 2008) .
Despite APAP being one of the most widely used drugs worldwide the relative contribution of individual UGT enzymes to APAP glucuronidation is yet to be completely resolved. Initial studies with recombinant UGT enzymes demonstrated that UGT1A1, UGT1A6 and UGT1A9 exhibit highest activity towards APAP (Bock et al., 1993; Court et al., 2001 ). However, more recently UGT2B15 has also been shown recently to catalyze APAP glucuronidation (Mutlib et al., 2006) . Consistent with these reports, UGT1A1, UGT1A6, UGT1A9 and UGT2B15 were all shown here to glucuronidate APAP (Figure 6 ), and APAP glucuronidation kinetic models differed between enzymes. Like these authors we found APAP glucuronidation by UGT1A1
and UGT2B15 followed sigmoidal and substrate inhibition kinetics, respectively.
Similarly, our data for UGT1A9 are in agreement with the sigmoidal kinetics reported 
